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ABSTRAK 
Tujuan: untuk mempelajari apakah ada efek protektif metformin terhadap sindrom frailty. Metode: 
studi dilakukan secara kasus kontrol pada subyek berusia ≥60 tahun yang berobat di poliklinik geriatri dan 
diabetes FKUI-RSCM, bulan Maret-Juni 2013. Diagnosis frailty ditegakkan menggunakan indeks frailty-40 
item (FI-40). Analisis statistik dengan metode chi-square untuk bivariat dan regresi logistik untuk multivariat, 
semua data disertai dengan interval kepercayaan 95%. Hasil: sindrom frailty didapatkan pada 25% (n=59) 
subyek penelitian, sedangkan pre-frail pada 72% (n=170) subyek dan sisanya tergolong fit. Metformin 
ditemukan mempunyai hubungan dengan sindrom frailty pada usila dengan diabetes mellitus tipe 2, yang 
tetap bermakna setelah dilakukan analisis multivariat (adjusted OR 0,043; IK 95% 0,019 – 0,099; p<0,001). 
Kesimpulan: metformin bersifat protektif terhadap kejadian sindrom frailty pada usila dengan diabetes melitus 
tipe 2.
Kata kunci: frailty, diabetes mellitus, metformin, usia lanjut.
ABSTRACT
Aim: to explore the possibility of metformin protective effect on frailty syndrome. Methods: this was a case 
control study conducted in subjects’ ≥60 years old who visited the Geriatrics and Diabetes outpatient clinic 
of Cipto Mangunkusumo National Referral Hospital between March and June 2013. Diagnosis of frailty was 
established using the FI-40 item criteria. Statistical analysis was done with chi-square method for bivariate and 
logistic regression method in multivariate analysis, all data was accompanied with 95% confidence interval. 
Results: frailty syndrome was found in 25% of subjects (n=59), with median age of 72 years old (SD 6.27) and 
median of FI-40 item score was 0.18 (SD 0.085). Metformin was found to have a significant relationship with 
frailty syndrome in the elderly diabetics, which retained significant value after multivariate analysis (adjusted 
OR 0.043; 95% CI 0.019-0.099; p<0.001). Conclusion: metformin was shown to have protective effect against 
frailty syndrome in elderly diabetics.
Key words: frailty, diabetes mellitus, metformin, elderly.
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INTRODUCTION
Frailty, a syndrome that was caused by 
dysfunctional aging and considered as a 
transitional state between autonomy and 
complete dependency, now widely linked with 
type 2 diabetes mellitus (T2DM).1 Several clinical 
studies had shown that, insulin resistance and 
T2DM had been proven to raise the risk of frailty 
on the elderly. Furthermore, insulin resistance 
and prandial glucose level disturbances had 
been linked to one of the important component 
of frailty, which is sarcopenia. Obesity, which 
tightly linked to insulin resistance and T2DM, 
also linked to a state of sarcopenia which known 
as sarcopenic obesity.2-6
Oral anti-diabetic metformin has been linked 
with the inhibition of aging process through 
many laboratory studies. Studies from animal 
experiments, especially fruit flies and nematodes, 
had shown that metformin could prolong 
the species’ life span around 40 to 200%.7-10 
Furthermore, population studies conducted in 
diabetics had also shown that metformin was 
able to prevent macro-vascular comorbid, which 
was linked with accelerated aging.11 However, 
there was no direct data to show the effect 
of metformin to modulate elderly diabetics’ 
functional status and frailty syndrome’s risk.7-9
We conducted this study to explore the 
association between metformin use and the 
risk of frailty syndrome in diabetic elderly. We 
aimed to provide a scientific basis for further 
interventional studies on frail Indonesian elderly 
with metformin.
METHODS
The study was conducted with a case-
control design and applied to the patients of 
the Geriatric and Diabetes Outpatient Clinic 
of Cipto Mangunkusumo National Referral 
Hospital (RSCM), aged 60 years old or older. The 
recruitment was done between March-June 2013; 
data acquisition was gathered by questionnaire 
and direct measurement of anthropometric and 
functional status variables. Study samples are 
patients who fulfilled the inclusion/exclusion 
criteria, and then categorized as: case (frail 
individuals according to FI-40 item criteria12 
(see online appendix: www.inaactamedica.org/
archives/2014/appendix/sumantri_vol.46-p.183.
pdf) and control (non frail individuals, randomly 
selected from the same catchment area as case). 
We excluded patients with: 1) Severe renal 
impairment (creatinine >2.0 g/dL and/or CCT 
<30 ml/min); 2) Liver cirrhosis; 3) Severe 
cardiac impairment (NYHA functional class 
III/IV) and 4) Severe lung impairment (COPD 
GOLD stage III/IV).
Bivariate analysis with chi square method 
was used to determine the relation between 
metformin use and frailty risk. Multivariate 
analysis with logistic regression was done to 
explore the influence of variables such as gender, 
age group, body mass index, diabetes control 
and length, and also comorbid such as chronic 
kidney disease stage I-III, COPD GOLD I-II, 
chronic liver disease and also chronic heart 
failure NYHA I-II.
This research was done with respect to 
patient’s autonomy and integrity; it fulfills the 
ethical principles of the Helsinki Declaration and 
has ethical clearance from the Research Ethical 
Committee of University of Indonesia Faculty of 
Medicine (no. 250/H2FI/ETIK/2013).
RESULTS
We managed to recruite a total of 236 
subjects (59 cases: 177 controls) from the 
estimated minimal sample size of 212 subjects 
(53 cases: 159 controls). Most of the subjects 
is female (57.6%; n=136), aged between 60-69 
years old (50%; n=118); and with a median age 
of 69.5 years old (range 60-87 years; SD 6.24 
years). The body mass index (BMI) showed a 
median of 24.4 (range 15.2-41.3; SD 4.08) and 
diabetes length of median 13 years (range 2-38 
years; SD 8.043). 
Metformin use showed a percentage of 
73.7% (n=175) among the subjects, which 45.3% 
(n=107) of them use it since the diagnosis of 
diabetes and 15.3% (n=36) never used it at all. 
The length of metformin use showed a median 
12 years (range 1-33 years; SD 7.69).
Frailty syndrome, with Frailty Index 40 item 
(FI-40) criteria, was found in 25% (n=59) of 
subjects, with pre-frail on 72% (n=170) subjects 
and the rest is fit/robust. The median score of 
FI-40 was 0.18 (range 0.05-0.475; SD 0.085), 
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with the median for frail group is 0.3 (range 0.25-
0.475; SD 0.061) and non-frail 0.16 (range 0.05-
0.244; SD 0.044). The subject’s characteristic is 
described in Table 1.
Analysis on the Relationship between 
Metformin and Frailty
Chi square analysis on the risk of frailty 
in metformin users and non-users, showed a 
difference in frailty risk (OR 0.039; 95% CI 
0.018-0.083; p<0.001). Then we conducted 
multivariate analysis by entering the agreed 
variables that fulfilled the requirements (p<0.25) 
into logistic regression. The variables that meet 
the requirements are age ≥80 year’s old, length 
of T2DM, and also kidney, respiratory, hepatic 
and cardiac comorbid. The analysis showed 
the risk of frailty between metformin users and 
non-users is 0.043 (adjusted OR; 95% CI 0.019-
0.099; p<0.001).
Sub-group analysis then conducted to 
compare individuals that already received 
diabetes’ therapy for 10 years or more. Individuals 
with metformin use since diagnosis (n=107) 
compared to metformin naive individuals (n=36) 
showed difference in terms of FI 40 score 
(0.17 vs. 0.30; 95% CI 0.16-0.18 vs. 0.27-0.33; 
p<0.001), number of comorbid (CIRS score 
10.91 vs. 14.77; 95% CI 10.37-11.46 vs. 13.70-
15.85; p<0.001) and current kidney function 
(eGFR 58.92 vs. 47.6 ml/min; 95% CI 54.70-
63.14 vs. 42.30-53.08; p=0.004). Furthermore, 
metformin users showed difference in muscle 








 - 60-69 years 35,6 / 21 54,8 / 97
 - 70-79 years 47,5 / 28 39,5 / 70
 - 80 years or older 16,9 / 10 5,6 / 10
BMI class (%/n)
 - Underweight 7,3 / 4 5,3 / 9
 - Normal weight 29,1 / 16 25,3 / 43
 - Overweight-Obese 63,6 / 35 69,4 / 118
Diabetes length (%/n)  
 - <5 years 5,1 / 3 9,6 / 17
 - 5-10 years 13,6 / 8 24,3 / 43
 - >10 years 81,4 / 48 66,1 / 117
Diabetes control (%/n)*   
 - Good 32,2 / 19 32,8 / 58
 - Moderate 39 / 23 35 / 62
 - Bad 28,8 / 17 32,2 / 57
Number of comorbid CIRS (%/n)**   
 - High (score ≥10)  94,9 / 56  58,8 / 104
 - Low (score <10) 5,1 / 3 41,2 / 73
Comorbid (% positive/n)  
 - Cardiac 49,2 / 29 26,6 / 47
 - Respiratory 20,3 / 12 5,1 / 9
 - Kidney 66,1 / 39 41,2 / 73
 - Hepatic 6,8 / 4 2,8 / 5
* Good (A1C<7, GDP <100, GD2PP <140) Moderate (A1C 7-8, GDP <126, GD2PP <200) Bad (A1C >8, GDP >140, 
GD2PP >200); 
** CIRS = Cumulative Illness Rating Scale
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strength (handheld dynamometer 17.75 kg vs. 
14.91 kg; 95% CI 16.51-18.99 vs.12.64-17.18; 
p=0.046) and body balance (functional reach test 
26.07 cm vs. 20.65 cm; 95% CI 24.68-27.47 vs. 
16.72-24.59; p=0.011).
DISCUSSION
The median score of FI-40 item in this 
study’s subjects is 0.18 (range 0.05-0.475; SD 
0.085), which is higher than mean FI-40 item 
score on Song et al’s study (0.138±0.11).13 This is 
mainly because a difference in study population, 
where in this study we recruited the subjects from 
outpatient rather than general population like 
study of song, diabetes and its accompanying 
comorbid was a vital component of frailty 
diagnosis using FI-40 item criteria, hence the 
difference could be predicted before.
Relationship of Metformin and Frailty 
syndrome
Bivariate analysis in our study had shown 
that individuals with metformin use had lower 
frailty risk compared to non-users. This 96.1% 
(OR 0.039) risk reduction showed metformin’s 
ability to prevent deficit accumulation that 
could cause frailty. Multivariate analysis also 
showed that metformin is independently linked 
with the risk of frailty syndrome in elderly 
diabetics (adjusted OR 0.043). Further sub-
group analysis showed lower comorbidities in 
individuals who used metformin since the start of 
diabetes diagnosis (CIRS score 10.91 vs. 14.77) 
compared to the metformin naive. The estimated 
glomerular filtration rate (eGFR), as a measure 
of kidney function, also showed a higher value 
in individuals that used metformin from the start 
(eGFR 58.92 vs. 47.6 ml/min).
Large population study (>50.000 subjects) 
conducted in Sweden, showed that metformin 
is able to lower the incidence of cardiovascular 
comorbid and mortality risk better than other 
anti-diabetics (2-13% reduction compared to 
sulfonylureas and 18-35% to insulin).14 Our 
study showed that individuals with frailty had 
more comorbid; and metformin use from the 
start of diabetes diagnosis may have the ability to 
prevent that accumulation. Metformin’s ability to 
prevent cardiovascular complications and frailty, 
thought to result from its influence on the cellular 
aging process. Aging in diabetics happened 
in a much faster process than non-diabetics, 
this was in part caused by oxidative stress and 
the accumulation of advanced glycosylation 
end products (AGEs), which caused chronic 
inflammation and accelerated cellular damage 
and aging.2,15-19 Metformin in animal studies and 
new onset diabetics has shown able to restore the 
natural body’s antioxidant status, lower AGEs 
and inflammatory mediators’ level, which usually 
increases in diabetics.8,20-23
This study also showed that one of the reason 
of metformin’s ability in reducing frailty risk 
in the elderly is because its effect on muscle 
strength and balance. Metformin users in this 
study showed better muscle strength (handheld 
dynamometer 17.75 kg vs. 14.91 kg) and body 
balance (functional reach test 26.07 cm vs. 20.65 
cm). Metformin’s ability in improving muscle 
strength and balance is thought to result from its 
effect on peripheral insulin sensitivity. Studies 
had shown that metformin is able to improve 
peripheral muscle glucose uptake through its 
AMPK regulatory effect.23,24 Furthermore, a 
study that was conducted on acute catabolic 
state reveals that, the use of metformin could 
improve the patients’ ability to synthesize 
muscular protein.25 Frailty syndrome itself has 
been proven to be a chronic inflammatory state 
linked with insulin resistance and muscle protein 
catabolism.4-6,26-29
Until recently, there is no study that linked 
the use of metformin with frailty syndrome 
on elderly diabetics. Furthermore, studies that 
linked metformin with aging process had not 
directly explored its effects on human. However, 
animal studies had shown metformin’s ability to 
improve life span and decrease cancer incidence 
significantly.8 Furthermore, observational studies 
on human had shown the link between metformin 
use and a decreasing incidence of several types 
of cancer in diabetics.9,30-35 Metformin’s ability 
to significantly decrease cancer incidence is very 
important, because carcinogenesis is considered 
as one of the consequences of accelerated and 
dysfunctional aging.31,35-37
Metformin was also considered to regulate 
aging with the same mechanism as caloric 
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restrictions through its effect on AMPK 
regulation.8 Studies on caloric restriction on 
several human cultures, the most famous among 
them is the Okinawa Study, had shown that, 
individuals with lower caloric consumption had 
increased life span.38 This Okinawa Study’s result 
has been corroborated by experimental animal 
studies on the effect of caloric restrictions, on 
the life span of several species of mammals and 
primates.8,39-41
Limitations of This Study
Due to case control design used, we could 
not exactly draw conclusion on the temporality 
between metformin use and frailty incidence. We 
also could not predict the relationship between 
metformin dose and the severity of frailty 
syndrome. This may in turn distort the picture 
of frailty that is presented in this study.
CONCLUSION
Metformin had a protective effect on the 
risk of frailty syndrome in elderly diabetics. It 
is independently linked with frailty in elderly 
diabetics.
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